Gilead Sciences (GILD) Tax Provisions (2009 - 2026)
Gilead Sciences' (GILD) quarterly Tax Provisions came in at $559.0 million in Q1 2026, up 67.37% YoY from $334.0 million in Q1 2025, and up 224.22% on a QoQ basis from -$450.0 million in Q4 2025.
Gilead Sciences (GILD) Tax Provisions (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Tax Provisions data on file, last reported at $559.0 million in Q1 2026.
- Quarterly Tax Provisions rose 67.37% year-over-year to $559.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 35.58% YoY) and the FY2025 annual result came in at $1.3 billion, up 509.48% from the prior year.
- Tax Provisions rose to $559.0 million in Q1 2026, from -$450.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $646.0 million in Q3 2022 to a low of -$450.0 million in Q4 2025.
- A 5-year average of $247.5 million and a median of $368.0 million in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2024 — Tax Provisions sank 303.42% — and 2025, when it soared 298.32%.
- Tracing GILD's Tax Provisions over 5 years: stood at $398.0 million in 2022, then sank by 40.45% to $237.0 million in 2023, then soared by 62.45% to $385.0 million in 2024, then sank by 216.88% to -$450.0 million in 2025, then surged by 224.22% to $559.0 million in 2026.
- The last three Tax Provisions figures came in at $559.0 million (Q1 2026), -$450.0 million (Q4 2025), and $589.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 242.00 Mn |
| Mar 31, 2026 | 559.00 Mn |
| Dec 31, 2025 | -450.00 Mn |
| Sep 30, 2025 | 589.00 Mn |
| Jun 30, 2025 | 468.00 Mn |
| Mar 31, 2025 | 334.00 Mn |
| Dec 31, 2024 | 385.00 Mn |
| Sep 30, 2024 | -297.00 Mn |
| Jun 30, 2024 | 438.00 Mn |
| Mar 31, 2024 | -315.00 Mn |
| Dec 31, 2023 | 237.00 Mn |
| Sep 30, 2023 | 146.00 Mn |
| Jun 30, 2023 | 549.00 Mn |
| Mar 31, 2023 | 316.00 Mn |
| Dec 31, 2022 | 398.00 Mn |
| Sep 30, 2022 | 646.00 Mn |
| Jun 30, 2022 | 368.00 Mn |
| Mar 31, 2022 | -164.00 Mn |
| Dec 31, 2021 | 383.00 Mn |
| Sep 30, 2021 | 852.00 Mn |